Patent ID: 6861423

Claim:
A method of reducing the development of a p38 mediated disorder, which method comprises: administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or salts thereof, wherein: R 1 is hydrogen or alkyl; R 2 is substituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl-alkyl, heterocyclyl, heterocyclyl spiro cycloalkyl, aralkoxy, alkoxy, -alkylene-S(O) n -alkyl (where n is 1 or 2) or —SO 2 Ar 2 ; R 3 is hydrogen, amino, monoalkylamino, dialkylamino, acylamino, —NR a C(—O)—R b (where R a is hydrogen or alkyl and R b is heterocyclyl or heteroalkyl), alkyl, cycloalkyl, phthalimidoalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(O)—R (where R is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl; and each of Ar 1 and Ar 2 is independently aryl; wherein said p38 mediated disorder is selected from the group consisting of Alzheimer's disease, adult respiratory distress syndrome, and chronic obstructive pulmonary disease.